serum
neutral
antibodi
titer
indic
protect
immun
coxsackieviru
enteroviru
two
main
etiolog
agent
hand
foot
mouth
diseas
hfmd
provid
basi
evalu
vaccin
efficaci
current
neutral
assay
base
inhibit
cytopath
effect
requir
manual
microscop
examin
timeconsum
laborintens
studi
highthroughput
neutral
assay
develop
employ
pseudovirus
express
luciferas
detect
infect
rhabdomyosarcoma
rd
cell
measur
serum
viral
neutral
antibodi
without
need
use
infecti
strain
neutral
antibodi
titer
could
determin
within
h
measur
luciferas
signal
assay
pseudoviru
neutral
assay
pcna
valid
comparison
convent
neutral
assay
ccna
test
human
serum
sampl
collect
children
age
year
neutral
antibodi
titer
determin
two
assay
well
correl
r
result
suggest
pcna
serv
rapid
object
procedur
measur
neutral
antibodi
hand
foot
mouth
diseas
hfmd
common
ill
children
effect
vaccin
antivir
drug
yet
avail
coxsackieviru
enteroviru
two
major
etiolog
agent
hfmd
hosoya
et
al
ang
et
al
solomon
et
al
seropreval
individu
age
year
found
nearli
rabenau
et
al
classifi
three
genogroup
sever
subgroup
c
base
phylogenet
analys
gene
hosoya
et
al
perera
et
al
zhou
et
al
chen
et
al
ill
caus
infect
usual
mild
chang
et
al
wherea
infect
often
associ
sever
complic
brainstem
enceph
sever
pulmonari
edema
shock
signific
mortal
wong
et
al
howev
recent
find
suggest
recombin
cocircul
zhang
et
al
may
contribut
increas
hfmd
case
china
past
year
zhang
et
al
furthermor
infect
alway
benign
fatal
case
associ
viru
report
cooper
et
al
wang
et
al
thu
understand
virolog
epidemiolog
import
develop
improv
diagnost
test
vaccin
serum
neutral
antibodi
respons
major
indic
infect
protect
immun
thu
use
evalu
vaccin
efficaci
hfmd
neutral
assay
base
inhibit
cytopath
effect
cpe
standard
method
recommend
world
health
organ
measur
neutral
antibodi
poliovirus
also
appli
wide
determin
neutral
antibodi
titer
chang
et
al
kung
et
al
howev
convent
neutral
assay
ccna
laborintens
subject
timeconsum
least
day
therefor
suitabl
mass
screen
protect
antibodi
seroepidemiolog
studi
recent
simplifi
neutral
assay
employ
pseudovirus
appli
detect
neutral
antibodi
multipl
envelop
virus
includ
influenza
sever
acut
respiratori
syndrom
coronoviru
sarscov
temperton
et
al
kobing
et
al
wright
et
al
hepat
c
viru
bartosch
et
al
keck
et
al
netski
et
al
human
immunodefici
viru
hiv
montefiori
rabi
wright
et
al
howev
packag
signal
poorli
understood
nonenvelop
virus
make
thu
far
difficult
packag
pseudovir
particl
detect
neutral
antibodi
human
serum
gener
describ
nonprolifer
pseudovirus
luciferaseencod
replicon
encapsid
viral
capsid
protein
tripl
transfect
cell
rna
polymeras
express
plasmid
rna
pol
plasmid
contain
reversetranscrib
fulllength
genom
encod
firefli
luciferas
gene
place
gene
capsid
express
plasmid
use
nonprolifer
pseudovirus
novel
neutral
assay
pcna
develop
neutral
antibodi
titer
could
determin
base
luciferas
signal
inocul
cell
within
h
result
suggest
pcna
may
serv
rapid
object
procedur
screen
neutral
antibodi
titer
rd
cell
human
embryon
rhabdomyosarcoma
cell
transfect
human
embryon
kidney
cell
cultur
monolay
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
strain
genotyp
gift
kindli
provid
henan
provinci
center
diseas
control
prevent
zhengzhou
china
grown
rd
cell
use
ccna
studi
human
sera
collect
children
age
year
henan
provinci
center
diseas
control
prevent
use
detect
neutral
antibodi
ccna
pcna
rna
extract
virusinfect
rd
cell
use
trizol
invitrogen
carlsbad
ca
usa
revers
transcrib
use
oligo
dt
primer
mmlv
revers
transcriptas
invitrogen
accord
manufactur
instruct
result
cdna
use
amplif
fragment
forward
primer
revers
primer
pcr
product
subclon
notixbai
site
vector
produc
rna
polymeras
gene
genbank
id
commerci
synthes
generay
bio
co
ltd
shanghai
china
insert
notixbai
site
vector
invitrogen
result
plasmid
rna
pol
express
rna
polymeras
control
strong
human
cmv
immedi
earli
promot
commerci
synthes
plasmid
genbank
id
contain
revers
transcrib
fulllength
genom
firefli
luciferas
gene
place
region
arita
et
al
includ
complet
nontransl
region
ntr
ntr
hepat
delta
viru
hdv
ribozym
rib
ad
downstream
ntr
follow
termin
troupin
et
al
transfect
plasmid
cell
rna
pol
express
rna
pol
drive
transcript
mrna
first
nucleotid
end
last
nucleotid
end
ribozym
cleavag
although
plasmid
carri
promot
addit
eukaryot
promot
sequenc
spontan
format
pseudoparticl
observ
transencapsid
capsid
protein
result
cotransfect
rna
pol
plasmid
fig
confluent
monolay
cell
flask
bd
bioscienc
franklin
lake
nj
usa
tripletransfect
rna
pol
g
use
l
lipofectamin
reagent
cat
invitrogen
incub
c
ml
dmem
fc
cell
wash
medium
replac
dmem
fc
h
posttransfect
incub
h
cell
harvest
store
c
supernat
tripletransfect
cell
collect
extract
equal
volum
chloroform
follow
rnase
mgml
dnase
uml
treatment
min
c
rtpcr
perform
use
revatraac
revers
transcriptas
takara
dalian
china
primer
pair
ntrf
lucr
pcr
product
purifi
use
pcr
purif
kit
tiangen
beij
china
direct
sequenc
analysi
carri
fulllength
genom
sequenc
genbank
id
use
dna
fragment
amplifi
rtpcr
templat
perform
electron
microscopi
pseudovirus
purifi
tripletransfect
cell
briefli
two
round
freez
thaw
transfect
cell
lysat
filter
membran
pseudovirus
purifi
result
suspens
use
deaesepharos
amersham
pharmacia
biotech
piscataway
nj
usa
horodniceanu
et
al
follow
centrifug
g
h
c
beckman
rotor
sucros
cushion
pellet
wash
three
time
distil
water
dissolv
l
phosphatebuff
salin
pb
sampl
examin
tem
jeol
datum
tokyo
japan
acceler
voltag
kv
imag
obtain
magnif
purifi
viru
stock
mix
sdspage
sampl
buffer
boil
separ
polyacrylamid
gel
protein
transfer
onto
pvdf
membran
western
blot
analysi
membran
probe
mous
polyclon
antibodi
gift
kindli
provid
nation
institut
food
drug
control
zhengzhou
china
dilut
pb
skim
milk
follow
correspond
alkalin
phosphatas
ap
conjug
secondari
antibodi
sigma
st
loui
mo
usa
dilut
membran
develop
chemiluminesc
use
nitroblu
tetrazolium
nbt
cat
dinguo
beij
china
bcip
cat
dinguo
number
nonprolifer
pseudoviru
particl
pseudoviru
titer
determin
measur
cell
cultur
infect
dose
ccid
use
microtitr
assay
perform
rd
cell
cultur
plate
bd
bioscienc
briefli
pseudovirus
supernat
collect
freezethaw
tripletransfect
cell
dilut
serial
dmem
fc
use
inocul
rd
cell
cell
per
well
quadrupl
per
dilut
plate
bd
bioscienc
incub
h
cell
harvest
measur
luciferas
activ
use
luciferas
assay
kit
cat
promega
madison
wi
usa
accord
manufactur
recommend
briefli
cell
lyse
addit
l
report
lysi
buffer
promega
luciferas
activ
cell
lysat
l
per
well
measur
use
fluoroskan
ascent
fl
micropl
fluoromet
thermo
scientif
waltham
usa
ccid
valu
determin
dilut
result
pseudoviru
infect
montefiori
time
control
cell
group
valu
cutoff
valu
determin
well
success
infect
ccid
reflect
titer
nonprolifer
pseudoviru
reflect
replicationcompet
viru
carri
pcna
optim
incub
time
pseudovirus
determin
briefli
rd
cell
per
well
seed
microtit
plate
use
medium
describ
incub
pseudovirus
multipl
infect
moi
ccid
per
cell
cell
wash
h
postinfect
hpi
luciferas
activ
cell
measur
design
time
point
h
pcna
human
serum
sampl
l
initi
dilut
dmem
supplement
fc
follow
serial
dilut
dilut
subsequ
l
dilut
serum
dmem
supplement
fc
mock
treatment
pseudoviru
posit
control
ad
plate
well
per
dilut
plate
pseudovirus
ccid
l
ad
well
plate
incub
c
h
incub
rd
cell
l
dmem
supplement
fc
ad
well
plate
incub
c
h
base
result
optim
experi
describ
luciferas
activ
infect
cell
measur
hpi
infect
calcul
percentag
luciferas
activ
cell
infect
pseudoviru
preincub
serum
rel
cell
infect
pseudoviru
posit
control
set
decreas
infect
threshold
valu
consid
posit
neutral
reciproc
highest
serum
dilut
show
infect
valu
equal
less
threshold
valu
determin
neutral
antibodi
titer
suspens
infecti
serial
dilut
incub
rd
cell
microtitr
plate
determin
viral
infect
titer
cpe
observ
use
invert
microscop
incub
period
day
tissu
cultur
infecti
dose
tcid
calcul
reed
muench
method
sera
heatinactiv
c
min
dilut
serial
mix
equal
volum
inoculum
l
contain
tcid
well
viru
c
h
microtit
plate
rd
cell
ad
well
incub
day
serum
sampl
test
triplic
neutral
titer
read
highest
dilut
complet
inhibit
cpe
well
posit
control
serum
known
titer
includ
run
result
obtain
least
three
replic
report
mean
standard
deviat
sd
statist
analys
carri
graphpad
prism
softwar
packag
group
compar
use
student
ttest
p
valu
consid
signific
motulski
christopoulo
obtain
pseudovirus
contain
firefli
luciferas
gene
place
gene
cell
tripletransfect
rna
pol
provid
sourc
protein
rna
pol
provid
sourc
rna
polymeras
transcrib
replicon
plasmid
two
day
transfect
cell
lyse
freezethaw
protein
encapsid
replicon
particl
express
luciferas
collect
supernat
clarifi
lysat
centrifug
pseudoviru
stock
titer
ccid
ml
rtpcr
primer
ntrf
lucr
perform
test
product
pseudoviru
particl
supernat
transfect
cell
pcr
product
kb
correspond
fragment
expect
primer
obtain
fig
lane
nucleotid
sequenc
segment
found
match
complet
align
sequench
softwar
format
pseudovirus
also
confirm
western
blot
fig
reveal
specif
band
kda
fig
lane
correspond
expect
size
viral
protein
furthermor
tem
analys
reveal
virallik
particl
nm
diamet
consist
shape
size
wildtyp
viru
fig
kinet
pattern
infect
first
determin
measur
luciferas
activ
infect
rd
cell
time
cours
fig
hpi
luciferas
activ
peak
gradual
decreas
time
differ
dose
pseudoviru
ccid
incub
serial
dilut
standard
mous
serum
contain
unit
neutral
antibodi
l
neutral
activ
evalu
ccna
shown
fig
standard
serum
could
neutral
infect
pseudovirus
rang
titer
test
good
doserespons
relationship
luciferas
signal
antiserum
dilut
viru
input
ccid
well
therefor
viru
dose
incub
time
h
use
subsequ
assay
pcna
carri
human
serum
sampl
result
compar
obtain
ccna
data
analyz
use
variou
threshold
level
order
determin
valu
would
give
neutral
antibodyposit
rate
sampl
percentag
sampl
show
neutral
antibodi
titer
closest
determin
ccna
fig
threshold
valu
infect
good
correl
observ
neutral
antibodi
titer
determin
ccna
pcna
r
fig
statist
signific
differ
found
neutral
antibodi
titer
ccna
pcna
p
disagr
observ
three
serum
sampl
ccna
neg
pcna
low
posit
titer
fig
thu
seem
like
three
sampl
extrem
low
titer
pcna
sensit
ccna
assumpt
also
support
observ
neutral
antibodi
titer
measur
use
pcna
higher
measur
ccna
fig
howev
sera
differ
neutral
antibodi
titer
determin
two
method
fig
neutral
titer
sever
serum
sampl
exceed
highest
dilut
use
studi
therefor
exact
correl
coeffici
could
obtain
pseudotyp
report
virus
provid
safe
quantit
highthroughput
tool
assess
antibodi
neutral
mani
envelop
virus
pseudovirus
undergo
step
infect
includ
attach
fusion
express
report
gene
form
infecti
progeni
due
lack
viral
structur
gene
need
sever
step
viral
life
cycl
thu
pseudovirus
propag
beyond
singl
cycl
infect
studi
nonprolifer
pseudovirus
gener
encapsid
luciferaseencod
replicon
viral
capsid
protein
via
tripl
transfect
cell
assay
base
pseudovirus
measur
neutral
antibodi
titer
human
serum
develop
direct
comparison
neutral
antibodi
titer
reveal
good
correl
pcna
ccna
fig
pcna
appear
sensit
fig
improv
sensit
like
attribut
inabl
pseudovirus
undergo
multipl
cycl
replic
due
lack
gene
inde
neutral
pseudovirus
therefor
achiev
neutral
antibodi
inhibit
initi
bind
virus
cell
serum
neutral
assay
employ
replicationcompet
virus
multipli
success
enter
cell
typic
greater
level
neutral
antibodi
requir
inhibit
viral
spread
often
result
appar
lower
neutral
titer
cost
ccna
low
requir
least
day
complet
manual
microscop
examin
special
expertis
may
produc
subject
variat
among
oper
laboratori
studi
process
time
pcna
shorten
h
fig
use
pseudovirus
detect
luciferas
signal
measur
infect
therefor
pseudoviru
neutral
assay
establish
studi
demonstr
sensit
safe
rapid
object
therefor
especi
suit
rapid
highthroughput
screen
sera
pseudoviru
neutral
assay
threshold
valu
arbitrarili
set
within
rang
gener
give
result
correl
well
obtain
convent
assay
especi
determin
neutral
antibodyposit
rate
fukushi
et
al
tamin
et
al
wang
et
al
finetun
threshold
valu
may
use
link
result
obtain
differ
neutral
method
studi
pcna
threshold
valu
gave
antibodyposit
rate
closest
obtain
ccna
fig
classifi
three
genogroup
sever
subgroup
c
studi
gene
genogroup
test
pcna
howev
possibl
interchang
gene
genogroup
sinc
capsid
protein
differ
genogroup
even
found
capabl
transencapsid
replicon
data
shown
therefor
pcna
may
conveni
quickli
adapt
test
antibodi
neutral
genogroup
virus
provid
solid
platform
develop
highthroughput
surveil
system
hfmd
use
rural
clinic
asia
importantli
studi
also
pave
way
develop
safe
inexpens
vaccin
may
potenti
use
protect
children
infect
divers
genogroup
develop
prophylact
vaccin
hfmd
public
health
prioriti
mani
countri
asia
neutral
antibodi
respons
import
indic
evalu
immunogen
differ
vaccin
candid
studi
highthroughput
neutral
assay
use
nonprolifer
pseudoviru
develop
may
serv
sensit
safe
rapid
object
procedur
measur
neutral
antibodi
titer
human
serum
thu
pcna
provid
robust
method
coordin
global
surveil
